Cargando…

Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study

OBJECTIVE: High variabilities in tacrolimus (TAC) exposure are still problems that confuse physicians. TAC trough levels (TAC C(min)) fluctuated considerably after endoscopic retrograde cholangiopancreatography (ERCP) treatment in several liver transplant (LT) patients. We aimed to investigate the v...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Rongrong, Wang, Weili, Ma, Kuifen, Duan, Xin, Wang, Fangfang, Huang, Mingzhu, Zhang, Wei, Liang, Tingbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466563/
https://www.ncbi.nlm.nih.gov/pubmed/32973503
http://dx.doi.org/10.3389/fphar.2020.01252
_version_ 1783577842392498176
author Wang, Rongrong
Wang, Weili
Ma, Kuifen
Duan, Xin
Wang, Fangfang
Huang, Mingzhu
Zhang, Wei
Liang, Tingbo
author_facet Wang, Rongrong
Wang, Weili
Ma, Kuifen
Duan, Xin
Wang, Fangfang
Huang, Mingzhu
Zhang, Wei
Liang, Tingbo
author_sort Wang, Rongrong
collection PubMed
description OBJECTIVE: High variabilities in tacrolimus (TAC) exposure are still problems that confuse physicians. TAC trough levels (TAC C(min)) fluctuated considerably after endoscopic retrograde cholangiopancreatography (ERCP) treatment in several liver transplant (LT) patients. We aimed to investigate the variation regularity of TAC C(min) post-ERCP and related factors. METHODS: This study was a retrospective, observational study conducted at the First Affiliated Hospital of Zhejiang University in China. From October 2017 to January 2019, 26 LT patients that received ERCP were included (73 TAC C(min) measures). The absolute difference and the variation extent in TAC C(min) pre- and post-ERCP were analyzed. Patients were divided into mild and obvious variation groups, and the differences were compared. RESULTS: The TAC C(min) in LT patients significantly increased in the first three days post-ERCP (p<0.05) and increased by more than 20% in 18 out of 26 (69.2%) patients. The mean extent of variation in TAC C(min) was 45.1% (95% confidence interval [CI]: 28.3–81.3%) and 31.4% (95% CI: 9.7–53.1%) on days 1 and 3 post-ERCP, respectively. The increasing TAC C(min) gradually returned to baseline within a week (p>0.05). The daily TAC dose and total bile acid (TBA) level were significantly higher (p<0.05) in patients with obvious variation in TAC C(min). The differences in other demographics, clinical characteristics, variation in laboratory data, and serum amylase levels between the two groups were not significant. CONCLUSION: The TAC C(min) significantly increased in LT patients during the first three days after ERCP, and the level returned to baseline within a week. The daily TAC dose and TBA levels may be related to this increase. Frequent drug concentration monitoring should be executed in the early phase post-ERCP, especially in patients with related factors.
format Online
Article
Text
id pubmed-7466563
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-74665632020-09-23 Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study Wang, Rongrong Wang, Weili Ma, Kuifen Duan, Xin Wang, Fangfang Huang, Mingzhu Zhang, Wei Liang, Tingbo Front Pharmacol Pharmacology OBJECTIVE: High variabilities in tacrolimus (TAC) exposure are still problems that confuse physicians. TAC trough levels (TAC C(min)) fluctuated considerably after endoscopic retrograde cholangiopancreatography (ERCP) treatment in several liver transplant (LT) patients. We aimed to investigate the variation regularity of TAC C(min) post-ERCP and related factors. METHODS: This study was a retrospective, observational study conducted at the First Affiliated Hospital of Zhejiang University in China. From October 2017 to January 2019, 26 LT patients that received ERCP were included (73 TAC C(min) measures). The absolute difference and the variation extent in TAC C(min) pre- and post-ERCP were analyzed. Patients were divided into mild and obvious variation groups, and the differences were compared. RESULTS: The TAC C(min) in LT patients significantly increased in the first three days post-ERCP (p<0.05) and increased by more than 20% in 18 out of 26 (69.2%) patients. The mean extent of variation in TAC C(min) was 45.1% (95% confidence interval [CI]: 28.3–81.3%) and 31.4% (95% CI: 9.7–53.1%) on days 1 and 3 post-ERCP, respectively. The increasing TAC C(min) gradually returned to baseline within a week (p>0.05). The daily TAC dose and total bile acid (TBA) level were significantly higher (p<0.05) in patients with obvious variation in TAC C(min). The differences in other demographics, clinical characteristics, variation in laboratory data, and serum amylase levels between the two groups were not significant. CONCLUSION: The TAC C(min) significantly increased in LT patients during the first three days after ERCP, and the level returned to baseline within a week. The daily TAC dose and TBA levels may be related to this increase. Frequent drug concentration monitoring should be executed in the early phase post-ERCP, especially in patients with related factors. Frontiers Media S.A. 2020-08-19 /pmc/articles/PMC7466563/ /pubmed/32973503 http://dx.doi.org/10.3389/fphar.2020.01252 Text en Copyright © 2020 Wang, Wang, Ma, Duan, Wang, Huang, Zhang and Liang http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Wang, Rongrong
Wang, Weili
Ma, Kuifen
Duan, Xin
Wang, Fangfang
Huang, Mingzhu
Zhang, Wei
Liang, Tingbo
Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study
title Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study
title_full Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study
title_fullStr Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study
title_full_unstemmed Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study
title_short Variation in Tacrolimus Trough Concentrations in Liver Transplant Patients Undergoing Endoscopic Retrograde Cholangiopancreatography: A Retrospective, Observational Study
title_sort variation in tacrolimus trough concentrations in liver transplant patients undergoing endoscopic retrograde cholangiopancreatography: a retrospective, observational study
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7466563/
https://www.ncbi.nlm.nih.gov/pubmed/32973503
http://dx.doi.org/10.3389/fphar.2020.01252
work_keys_str_mv AT wangrongrong variationintacrolimustroughconcentrationsinlivertransplantpatientsundergoingendoscopicretrogradecholangiopancreatographyaretrospectiveobservationalstudy
AT wangweili variationintacrolimustroughconcentrationsinlivertransplantpatientsundergoingendoscopicretrogradecholangiopancreatographyaretrospectiveobservationalstudy
AT makuifen variationintacrolimustroughconcentrationsinlivertransplantpatientsundergoingendoscopicretrogradecholangiopancreatographyaretrospectiveobservationalstudy
AT duanxin variationintacrolimustroughconcentrationsinlivertransplantpatientsundergoingendoscopicretrogradecholangiopancreatographyaretrospectiveobservationalstudy
AT wangfangfang variationintacrolimustroughconcentrationsinlivertransplantpatientsundergoingendoscopicretrogradecholangiopancreatographyaretrospectiveobservationalstudy
AT huangmingzhu variationintacrolimustroughconcentrationsinlivertransplantpatientsundergoingendoscopicretrogradecholangiopancreatographyaretrospectiveobservationalstudy
AT zhangwei variationintacrolimustroughconcentrationsinlivertransplantpatientsundergoingendoscopicretrogradecholangiopancreatographyaretrospectiveobservationalstudy
AT liangtingbo variationintacrolimustroughconcentrationsinlivertransplantpatientsundergoingendoscopicretrogradecholangiopancreatographyaretrospectiveobservationalstudy